Macrogenics Stock Performance
| MGNX Stock | USD 3.34 0.14 4.02% |
The company secures a Beta (Market Risk) of -0.0014, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning MacroGenics are expected to decrease at a much lower rate. During the bear market, MacroGenics is likely to outperform the market. At this point, MacroGenics has a negative expected return of -0.0708%. Please make sure to verify MacroGenics' downside variance, and the relationship between the total risk alpha and daily balance of power , to decide if MacroGenics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days MacroGenics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, MacroGenics is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 2.1 | Year To Date Return (66.50) | Ten Year Return (88.51) | All Time Return (86.35) |
1 | MGNX Deadline Rosen Law Firm Urges MacroGenics, Inc. Stockholders with Large Losses in Excess of 100K to Contact the Firm for Information About Their Rights | 09/17/2024 |
2 | MacroGenics, Inc. Securities Fraud Class Action Lawsuit Pending Contact Levi Korsinsky Before September 24, 2024 to Discuss Your Rights - MGNX | 09/20/2024 |
3 | Class Action Filed Against MacroGenics, Inc. Seeking Recovery for Investors - Contact Levi Korsinsky | 09/24/2024 |
4 | Acquisition by Koenig Scott of 374215 shares of MacroGenics subject to Rule 16b-3 | 09/25/2024 |
5 | Disposition of 53265 shares by Koenig Scott of MacroGenics subject to Rule 16b-3 | 10/07/2024 |
6 | MacroGenics Q3 2024 Earnings Preview | 11/04/2024 |
7 | MacroGenics Q3 Earnings Snapshot | 11/05/2024 |
8 | MacroGenics Beats Q3 Earnings and Revenue Estimates | 11/06/2024 |
9 | MacroGenics Third Quarter 2024 Earnings Beats Expectations | 11/07/2024 |
10 | MacroGenics SWOT analysis biotech stock faces pipeline hurdles amid cash strength | 11/13/2024 |
11 | MacroGenics Announces CEO Transition Amidst Strong Growth - MSN | 11/20/2024 |
12 | Breast Cancer Therapeutics Global Market Research 2024 Advancements in Targeted and Immunotherapies Revolutionize Treatment - Forecasts to 2030 | 12/02/2024 |
| Begin Period Cash Flow | 108.9 M |
MacroGenics |
MacroGenics Relative Risk vs. Return Landscape
If you would invest 370.00 in MacroGenics on September 13, 2024 and sell it today you would lose (36.00) from holding MacroGenics or give up 9.73% of portfolio value over 90 days. MacroGenics is currently does not generate positive expected returns and assumes 4.3188% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than MacroGenics, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
MacroGenics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MacroGenics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as MacroGenics, and traders can use it to determine the average amount a MacroGenics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0164
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MGNX |
Estimated Market Risk
| 4.32 actual daily | 38 62% of assets are more volatile |
Expected Return
| -0.07 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average MacroGenics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MacroGenics by adding MacroGenics to a well-diversified portfolio.
MacroGenics Fundamentals Growth
MacroGenics Stock prices reflect investors' perceptions of the future prospects and financial health of MacroGenics, and MacroGenics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MacroGenics Stock performance.
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (0.69) % | ||||
| Operating Margin | 0.49 % | ||||
| Current Valuation | 47.76 M | ||||
| Shares Outstanding | 62.76 M | ||||
| Price To Earning | (4.54) X | ||||
| Price To Book | 1.78 X | ||||
| Price To Sales | 1.51 X | ||||
| Revenue | 58.75 M | ||||
| Gross Profit | (62.47 M) | ||||
| EBITDA | 2.02 M | ||||
| Net Income | (9.06 M) | ||||
| Cash And Equivalents | 133.74 M | ||||
| Cash Per Share | 2.18 X | ||||
| Total Debt | 33.97 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 3.30 X | ||||
| Book Value Per Share | 1.91 X | ||||
| Cash Flow From Operations | (78.2 M) | ||||
| Earnings Per Share | (1.57) X | ||||
| Market Capitalization | 214.02 M | ||||
| Total Asset | 298.42 M | ||||
| Retained Earnings | (1.1 B) | ||||
| Working Capital | 195.23 M | ||||
| Current Asset | 342.38 M | ||||
| Current Liabilities | 23.29 M | ||||
About MacroGenics Performance
Evaluating MacroGenics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if MacroGenics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MacroGenics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 54.20 | 51.49 | |
| Return On Tangible Assets | (0.03) | (0.03) | |
| Return On Capital Employed | (0.69) | (0.66) | |
| Return On Assets | (0.03) | (0.03) | |
| Return On Equity | (0.06) | (0.06) |
Things to note about MacroGenics performance evaluation
Checking the ongoing alerts about MacroGenics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MacroGenics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MacroGenics generated a negative expected return over the last 90 days | |
| MacroGenics has high historical volatility and very poor performance | |
| MacroGenics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 58.75 M. Net Loss for the year was (9.06 M) with loss before overhead, payroll, taxes, and interest of (62.47 M). | |
| MacroGenics currently holds about 133.74 M in cash with (78.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.18. | |
| MacroGenics has a poor financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Breast Cancer Therapeutics Global Market Research 2024 Advancements in Targeted and Immunotherapies Revolutionize Treatment - Forecasts to 2030 |
- Analyzing MacroGenics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MacroGenics' stock is overvalued or undervalued compared to its peers.
- Examining MacroGenics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MacroGenics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of MacroGenics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MacroGenics' stock. These opinions can provide insight into MacroGenics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for MacroGenics Stock Analysis
When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.